Creating an effective HIV vaccine has long been a scientific holy grail, but one major roadblock has persisted: getting the body to produce the right immune cells and antibodies to fight the virus. Imagine a vaccine that could finally crack this code, offering hope for millions. Traditional vaccines use protein scaffolds to deliver HIV proteins, but here's the catch: the immune system often attacks the scaffold itself instead of focusing solely on HIV. This misdirected response weakens the vaccine's effectiveness.
But a groundbreaking study published in Science (https://doi.org/10.1126/science.adx6291) on February 5, 2026, introduces a game-changing solution. Researchers from Scripps Research and MIT have developed a revolutionary vaccine scaffold made from DNA—a material the immune system largely ignores. This ingenious approach eliminates those pesky off-target antibodies, allowing the immune system to zero in on HIV.
In their experiments, the team, led by Darrell Irvine (https://www.scripps.edu/faculty/irvine/), demonstrated that DNA-based scaffolds produced ten times more immune cells targeting a vulnerable site on HIV compared to traditional protein-based scaffolds. This suggests a more potent and precise immune response, bringing us closer to a protective HIV vaccine.
"This is a brand-new technology with the potential to revolutionize not just HIV vaccines, but also other challenging vaccine targets," says Irvine, a professor at Scripps Research and Howard Hughes Medical Institute Investigator. Think universal flu vaccines or pan-coronavirus vaccines—areas where every immune response counts.
And this is the part most people miss: traditional protein scaffolds, while effective for many vaccines, can trigger unwanted immune reactions against themselves. For HIV, where broadly protective B cells are incredibly rare, any distraction from the target could be critical. Irvine explains, "We knew protein scaffolds had this issue, but we didn’t realize how much they were hindering the immune response we truly need."
The team turned to DNA origami, a technique that folds DNA into precise 3D shapes. While data on DNA origami in vaccines is limited, one thing is clear: B cells, the antibody producers, don’t recognize DNA as a threat. This is nature’s way of preventing autoimmune reactions against our own DNA.
"Our earlier work with SARS-CoV-2 antigens showed that DNA scaffolds were immunologically silent, but we weren’t sure if they could also boost the right immune responses," says Mark Bathe (https://be.mit.edu/faculty/mark-bathe/), a biological engineer at MIT. "This study proves they can, marking a breakthrough for active immunotherapy."
The researchers designed DNA nanoparticles displaying 60 copies of an HIV envelope protein known to activate rare B cells capable of producing broadly neutralizing antibodies. In mice with human-like immune systems, nearly 60% of germinal center B cells—the antibody factories—focused on the HIV protein. In contrast, a protein-scaffolded vaccine (currently in clinical trials) achieved only 20%, with many cells targeting the scaffold instead.
The DNA-based vaccine showed a 25-fold improvement in the ratio of HIV-specific to off-target immune cells. Within two weeks, mice receiving the DNA vaccine had detectable levels of the rare B cells, while those receiving the protein vaccine had none.
The implications are vast. Beyond HIV, this technology could transform vaccines for influenza, coronaviruses, and other elusive pathogens. "These vaccines require activating incredibly rare immune cells," Irvine notes. "DNA origami scaffolds could be the key to overcoming this challenge."
Now, Irvine and Bathe are exploring how DNA scaffold shapes affect vaccine effectiveness and testing their long-term safety. But here's where it gets controversial: Could DNA-based scaffolds completely replace protein scaffolds in vaccine development? Or will they remain a niche solution for the toughest cases? Weigh in below—what do you think?
Reference: Romanov A, Knappe GA, Ronsard L, et al. DNA origami vaccines program antigen-focused germinal centers. Sci. 2026;391(6785):eadx6291. doi:10.1126/science.adx6291 (https://doi.org/10.1126/science.adx6291)
This article is republished from Scripps Research (https://www.scripps.edu/news-and-events/press-room/2026/20260205-irvine-vaccine-scaffolding.html). Material may have been edited for clarity and length. For more information, contact the cited source. Our republishing policy is available here (https://www.technologynetworks.com/tn/editorial-policies#republishing).
